Richard D. Pilnik - 01 Jun 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Director
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2022, 16:38:52 UTC
Previous filing: 03 Jan 2022
Next filing: 05 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						119,327	01 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+18,510		$0.000000	18,510	01 Jun 2022	Common Shares	18,510	$2.45	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 43,649 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan.
F2	Vests in four nearly equal quarterly installments over one year.